Synergy Strips Corp. Names New Executive Vice President
01 May 2015 --- Synergy Strips Corp., a company that markets and distributes consumer products primarily in the health and wellness industry, announces that Luc Vanhal has been named Executive Vice President, Direct to Consumer Division. Based on the company’s growth strategy, and proven success in our retail sector, this role is key to our management team. Vanhal has extensive experience in U.S. and international marketing of health-related products as COO of NAC Marketing, as well as CFO and COO of Guthy-Renker.
“We are pleased to welcome Luc to the Synergy team,” says Jack Ross, CEO, Synergy Strips Corp. “His diverse background in marketing consumer products will be an asset in expanding market share for our various product lines.”
Vanhal holds a master’s of business administration from the University of Leuven, Belgium. Prior to joining Synergy Strips, his background also includes CFO of consumer products for The Walt Disney Company, president and COO of Vivendi Universal Games and COO of Belkin.
Synergy’s acquisition of the FOCUSfactor brand early this year comes after a rare achievement in the nutritional supplement category – a patent on the product’s proprietary formulation. In December 2012, the United States Patent and Trademark Office issued U.S. Patent 8,329,227 covering FOCUSfactor’s proprietary formulation “for enhanced mental function.” The issuance of the patent marked one of the few times a patent has been issued for a nationally branded nutritional supplement.
The issuance of the patent for FOCUSfactor came after a 2011 clinical study report which showed that FOCUSfactor improves memory, concentration and focus in healthy adults. The clinical study of FOCUSfactor was sponsored by Factor Nutrition Labs and was conducted by Cognitive Research Corporation, a full-service contract research organization that specializes in the effects of nutritional supplements and pharmaceutical products on human cognition. The study was conducted in compliance with all applicable country requirements for the conduct of clinical studies, including those outlined by the International Conference on Harmonization, Consolidated Guidelines on Good Clinical Practices, and the Food and Drug Administration.
